CAMBRIDGE — The symbolism was unmistakable.
Three weeks after firing its high-profile chief executive, causing investors to fear a retreat from its global strategy, French drug maker Sanofi SA hosted a daylong meeting with analysts Thursday here at the headquarters of Genzyme, the biotech Sanofi snapped up three years ago to inject a dose of entrepreneurial vigor.
The message was that Sanofi, long slow to innovate, will be bringing a new generation of therapies to market, including a pair of newly approved Genzyme medicines to treat multiple sclerosis and Gaucher disease.
Help employers find you! Check out all the jobs and post your resume.
